Take MUC16 and IDH1 as examples: past GC studies have illustrated that MUC16 mutations could activate the p53 pathway and DNA repair pathway, which are all tumor suppressor pathways [42,43]; thus, improved outcomes of GC might be expected from mutated MUC16 [34,36]. This evidence concerns the gene TP53 and gastric cancer.